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Background: The INtubation-SURfactant-Extubation (INSURE) is a procedure that is increasingly being used to treat
the respiratory distress syndrome in preterm infants. The objective of this study was to identify predictors for an
unsuccessful INSURE procedure.
Methods: The neonates included were less than 32 weeks’ gestation, treated with surfactant in the neonatal
intensive care unit, and born 1998–2010. INSURE was defined as surfactant administration during intubation for less
than 2 hours without the need for mechanical ventilation. INSURE success was defined as no re-intubation within
72 hours after INSURE, and INSURE failure was defined as re-intubation within 72 hours after INSURE. An unsuccessful
INSURE procedure was either INSURE failure or mechanical ventilation for more than 24 hours immediately after
surfactant administration. All predictors were defined a priori and were present before surfactant administration.
Multivariate logistic regression was performed.
Results: In total, 322 neonates were included: 31% (n = 100) had INSURE success, 10% (n = 33) had INSURE failure,
49% (n = 158) needed mechanical ventilation for more than 24 hours, and the remaining 10% (n = 31) needed
mechanical ventilation for less than 24 hours. Predictors for INSURE failure were low gestational age and
hemoglobin below 8.5 mmol/l. Predictors for mechanical ventilation for more than 24 hours were low gestational
age, Apgar at 5 minutes below 7, oxygen need above 50%, CO2 pressure above 7 kPa (~53 mmHg), pH below 7.3,
lactate above 2.5 mmol/l, need for inotropes, and surfactant administration shortly after birth, whereas
preeclampsia reduced the risk.
Conclusions: We identified specific predictors associated with an unsuccessful INSURE procedure. Keeping
high-risk neonates with one or several predictors intubated and treated with mechanical ventilation after
surfactant may prevent a re-intubation procedure.
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Continuous positive airway pressureBackground
The respiratory distress syndrome (RDS) can be treated ac-
cording to the INtubation-SURfactant-Extubation (INSURE)
procedure [1]. However, INSURE failure, with the need
for re–intubation and mechanical ventilation (MV), is
common [2-7]. Keeping neonates at high risk of INSURE
failure intubated on MV after surfactant may prevent a* Correspondence: tbh@dadlnet.dk
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unless otherwise stated.re-intubation procedure, which may decrease the morbid-
ity and mortality of the neonates because re-intubation is
associated with airway injuries [8], blood pressure devia-
tions, and post-extubation atelectasis [9].
No randomized controlled trials have directly evaluated
the efficacy of INSURE in extremely preterm neonates
(<28 weeks gestation) [1]. In some of these infants treat-
ment with MV after surfactant might be a better option
due to the high risk of INSURE failure. When a neonate
with RDS needs surfactant in our department, the attend-
ing neonatologist decides, based on clinical evaluation,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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INSURE or with MV immediately after surfactant. In-
fants experiencing INSURE failure and infants needing
MV for more than 24 hours immediately after surfac-
tant can be regarded as having had an unsuccessful
INSURE procedure.
Two studies have assessed predictors of INSURE failure
[5,6]. The authors report that an increased risk of INSURE
failure was found in neonates with low birth weight, high
partial pressure of carbon dioxide (pCO2), low arterial-
alveolar oxygen tension ratio (a/A-ratio), severe RDS on
chest x-ray, and low partial pressure of arterial oxygen
to fraction of inspired oxygen ratio (pO2/FiO2-ratio)
[5,6]. We report here findings in a considerably larger
study population than in the two studies mentioned
above, and we are the first to suggest that predictors for
MV for more than 24 hours might also predict INSURE
failure.
In this paper we identify predictors associated with an
unsuccessful INSURE procedure defined as either INSURE
failure or MV for more than 24 hours, in contrast to the
two papers that describe INSURE failure [5,6].
Methods
The Danish National Board of Health and the Danish
Data Protection Agency approved the study. We con-
ducted a historical cohort study based on data from
medical records concerning admissions to the neonatal
intensive care unit (NICU) and on the Aarhus Birth
Cohort (ABC), which has been described in detail else-
where [10,11]. In brief, the ABC included all women
scheduled for delivery at Aarhus University Hospital,
Denmark (AUH), and contains information on delivery,
clinical state of the neonate immediately after birth, and
information on neonates admitted to the NICU (complete
from 1998). Using the ABC, neonates with the following
characteristics were identified: born 1998–2010, born at
AUH, born prior to 32 completed weeks of gestation, and
treated with surfactant. Neonates receiving surfactant
as part of emergency intubation for resuscitation in the
delivery room were excluded.
The predictors based on information from the ABC
included antenatal steroids, cesarean delivery vs. vaginal
delivery, preeclampsia, prolonged rupture of mem-
branes >18 hours, maternal age at delivery, parity, mul-
tiple pregnancy, gender, Apgar score 1 and 5 minutes
after birth, and umbilical cord standard base excess
(SBE) and pH. Predictors obtained from the medical
records included gestational age, birth weight, small for
gestational age (SGA) defined as below the 10th per-
centile according to the formula developed by Marsal
et al. [12], first temperature within 6 hours of admission
to the NICU, last mean arterial blood pressure within
4 hours before intubation, hours from birth to surfactantadministration, and whether inotropes were given prior to
intubation. The following predictors were collected within
2 hours before intubation: FiO2, pO2 (transcutaneous or
arterial), pCO2 (transcutaneous, capillary or arterial), and
a/A-ratio estimated by the formula: arterial pO2 in kPa/
(95 × FiO2 – arterial pCO2 in kPa). The following predic-
tors were collected within 5 hours before intubation: pH,
SBE, lactate, and hemoglobin. Predictors were present
prior to surfactant administration (i.e., prior to the know-
ledge of the need for intubation). Furthermore, predictors
were defined prior to analyses based on former studies
and clinical experience [5,6].
Post-surfactant characteristics were identified but were
not in strict sense present before surfactant administration
in all neonates and were therefore not regarded as predic-
tors. Post-surfactant characteristics were the clinical risk
index for babies [13], infusions given within 6 hours after
surfactant including inotropes, packed red blood cells, and
volume expansion, antibiotics given for 7 days or more
and started within 24 hours after birth, necrotizing en-
terocolitis [14], patent ductus arteriosus, retinopathy of
prematurity grade III [15], periventricular leukomalasia
[16], intraventricular hemorrhage [17], and the following
respiratory variables: duration of MV, duration of nasal
continuous positive airway pressure (nCPAP), duration of
supplemental oxygen, neonatal mortality, and BPD. BPD
was defined as needing supplemental oxygen, nCPAP, or
MV at 36 post-menstrual weeks. The neonate had no BPD
if transferred (without supplemental oxygen, nCPAP, or
MV) or discharged before 36 post-menstrual weeks. BPD
was regarded as missing if transferred before 36 post-
menstrual weeks with supplemental oxygen, nCPAP, or
MV. If the neonate died before 36 post-menstrual weeks,
the neonate was not included in analyses of BPD. Data
entry was done using EpiData 3.1 software (Odense,
Denmark).
INSURE was defined as surfactant administration during
intubation for less than 2 hours without the need for
mechanical ventilation. INSURE success was defined as no
re-intubation within 72 hours after INSURE, and INSURE
failure was defined as re-intubation within 72 hours after
INSURE. Neonates mechanically ventilated for ≤24 hours
were classified as short MV, and neonates mechanically
ventilated more than 24 hours was classified as long MV.
Non-mechanically ventilated neonates that were intubated
for more than 2 hours during surfactant administration
were defined as short MV (n = 1). Neonates with initial
MV ≤24 hours that were re-intubated within 72 hours
after extubation were defined as long MV (n = 7). Neo-
nates treated with INSURE or MV for ≤24 hours who
died within 72 hours after extubation were categorized
as follows: neonates who were extubated to receive pallia-
tive care (and thus died shortly after extubation) within
2 hours after the intubation-procedure with surfactant
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have required MV for more than 24 hours to survive; neo-
nates treated with INSURE who died within 72 hours after
extubation were defined as INSURE failures (n = 1), as-
suming they would have needed re-intubation and MV to
survive; neonates treated with MV for ≤24 hours who
were extubated to palliative care (n = 10) or who died
within 72 hours after extubation (n =2) were defined as
long MV, assuming they would have needed continued
MV for more than 24 hours or re-intubation to survive.
All groups were defined prior to the analyses.
In our unit, the indication for surfactant administration
was an a/A-ratio <0.22 for neonates with a gestational age
of 30 weeks or more and an a/A-ratio <0.36 for neonates
with a gestational age below 30 weeks according to the
studies by Verder et al. 1994 and 1999 [7,18]. This corre-
sponds to an FiO2 ≥ 0.55 and an FiO2 ≥ 0.35, respectively
[3]. The administered surfactant was Poractant Alfa
(Curosurf®, Chiesi Pharmaceuticals, Parma, Italy). After
delivery all neonates were stabilized on nCPAP initially on
5 cmH2O, with the possibility of adjustment to yield a pH
above 7.30 using Benveniste’s pediatric gas-jet valve
(Dameca, Copenhagen, Denmark). A loading dose of theo-
phyllamine (theophylline and ethylenediamine in 2:1 ratio)
or caffeine citrate was given immediately after admission
to the NICU. All neonates received pre-intubation medi-
cation and the vast majority received the following: atro-
pine 10–20 μg/kg, suxametonium 2 mg/kg, thiomebumal
2–5 mg/kg, and morphine 0.1 mg/kg. In case of insuffi-
cient breathing after surfactant, naloxone 0.1 mg/kg as
antidote could be given. After intratracheal administration
of 200 mg/kg surfactant and manual ventilation the neo-
nate was usually rapidly extubated to nCPAP. If there was
a high oxygen demand (FiO2 above 30%), a high transcuta-
neous CO2 (above 7.5 kPa), or a pH less than 7.20, the
neonate was kept intubated and treated with MV (Babylog
800+, Dräger, Lübeck, Germany). As our cohort dates
back to 1998, the optimal dosing of surfactant was not
established. Therefore, some neonates suspected of need-
ing MV after intubation were treated with an initial dose
of 100 mg/kg immediately after intubation and a repeated
dose of 100 mg/kg immediately after MV was initiated,
thus, receiving a total dose of 200 mg/kg. The indications
for MV after INSURE were acute respiratory insufficiency,
poor oxygenation with an a/A-ratio <0.15, and respiratory
acidosis (pH < 7.20) despite optimal nCPAP pressures.
The indication for extubation after MV was a FiO2 of less
than 0.40, peak inspiratory pressures less than 20–22 cm
H2O and set mechanical ventilation frequency less than
25–30 minute−1. Acute neonatal anemia was usually trans-
fused with 10–15 ml/kg packed red blood cells over 3 to
4 hours if hemoglobin was below 8.0 mmol/l.
Continuous variables were dichotomized prior to ana-
lyses using cut-off points regarded as clinically relevant.In the primary analyses, we estimated crude odds ratios
(OR) for each predictor for the risk of INSURE failure
using INSURE success as reference. The estimates were
adjusted for co-variates chosen a priori: gestational age
at birth (days), gender, and birth year in three groups
(1998–2002, 2003–2006, 2007–2010). ORs are presented
with 95% confidence intervals (CI). Gestational age was
assessed in four groups (<26 weeks, 26 + 0 to 27 + 6 weeks,
28 + 0 to 29 + 6 weeks, and 30 + 0 to 31 + 6 weeks) using
30 + 0 to 31 + 6 weeks as the reference. We fitted all ad-
justed models using robust standard errors to take into ac-
count the clustering of siblings. In the secondary analyses,
we compared the long MV group with the INSURE
success group.
We compared the post-surfactant characteristics in the
INSURE failure group, the short MV group, and the long
MV group with the INSURE success group; Wilcoxon
rank sum test was used for non-normally distributed
continuous variables and logistic regression for dichot-
omous variables. In case of missing values, a complete
case analysis was performed. The significance level was a
2-sided p value < 5%. The analyses were defined a priori.
The statistical analyses were performed using STATA/SE
12.1 software (StataCorp LP, Texas, USA).Results
The study population consisted of 322 neonates born be-
fore 32 weeks gestation, treated with surfactant, and born
1998–2010 (Figure 1). Characteristics of the study popula-
tion are presented in Table 1. In total, 31% (n = 100) had
INSURE success, 10% (n = 33) had INSURE failure, 10%
(n = 31) needed short MV, and 49% (n = 158) needed
long MV.
The predictors for INSURE failure (primary analyses)
are shown in Table 2. For each 2-week decrease in gesta-
tional age, the risk of INSURE failure increased with an
adjusted OR of 1.8 (95% CI: 1.2–2.8). Hemoglobin below
8.5 mmol/l was also associated with an increased risk of
INSURE failure. The predictors for long MV (secondary
analyses) are shown in Table 2. For each 2-week de-
crease in gestational age, the risk of long MV increased
with an adjusted OR of 3.1 (95% CI: 2.3–4.3). After adjust-
ment, Apgar at 5 minutes below 7, FiO2 above 0.50, pCO2
above 7 kPa (~53 mmHg), lactate above 2.5 mmol/l, pH
below 7.3, inotropes given prior to intubation, and surfac-
tant given within 5 hours after birth were all associated
with the need for long MV. Preeclampsia reduced the risk
of long MV.
The post-surfactant characteristics for the four treat-
ment groups are shown in Table 3. The INSURE success
group had characteristics similar to the short MV group,
and the INSURE failure group had characteristics similar
to the long MV group with respect to the following
11,799 admitted to NICU (1998-2010) 
10,619 born at AUH 
1,007 with GA <32 weeks 
363 treated with surfactant according to the ABC 
357 treated with surfactant after review 
1,180 not born at AUH 
9,612 with GA 32 weeks 
644 not treated with surfactant 
4 not treated with surfactant 
1 had surfactant after 2 weeks 
3 born at another hospital 
2 misclassified as born outside AUH1 
322 in final population 
35 intubated in delivery room 
Figure 1 Study population. Abbreviations: AUH, Aarhus University Hospital; GA, gestational age; NICU, neonatal intensive care unit.
174 neonates were born outside AUH according to the Aarhus Birth Cohort, but fulfilled the other inclusion criteria. Two of these neonates were
included as they were actually born at AUH.
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ation of nCPAP, and duration of oxygen supplementation.
Discussion
The risk of INSURE failure and long MV increased with
decreasing gestational age at birth. In addition, the pri-
mary analyses showed that low hemoglobin prior to
surfactant was a predictor for INSURE failure. Further-
more, the secondary analyses showed that low Apgar at
5 minutes, high FiO2, high pCO2, high lactate, low pH,
inotropes given prior to intubation, and surfactant ad-
ministered within 5 hours after birth were associated
with an increased risk of long duration of MV, whereas
preeclampsia reduced the risk.
Cherif et al. 2008 and Dani et al. 2010 previously
assessed predictors of INSURE failure defined as re-
intubation within 72 hours among neonates of 27–34
weeks’ gestation and below 30 weeks’ gestation, respect-
ively [5,6]. A short gestational age was not associated
with INSURE failure in these studies, but birth weight
was associated with INSURE failure even after adjust-
ment for potential confounding variables [5,6]. Due to
lack of difference in gestational age between the two
groups, gestational age was not included in the multi-
variate model [5,6]. We found no association between
birth weight or being SGA and INSURE failure after ad-
justment for gestational age.
The two previous studies that have identified neonates
with INSURE failure found that they had more severe
RDS in terms of low a/A-ratio, high pCO2, and low pO2/
FiO2 [5,6]. In the present study, similar predictors werefound for long duration of MV, but not for INSURE fail-
ure. This indicates that the neonatologist involved in our
study opted to treat neonates with more severe RDS with
MV. Thus, the influence of these specific predictors by
may be underestimated if INSURE failure is studied as the
outcome rather than considering unsuccessful INSURE as
a combination of INSURE failure and long MV.
A low hemoglobin concentration was associated with
INSURE failure. An explanation could be that the insuf-
ficient oxygen delivery to peripheral tissues increased
lactate and decrease pH. However, high lactate and low
pH were not associated with INSURE failure. Another
speculation might be that INSURE failure is associated
with poor perfusion and/or hypotension, and if treated
with volume expansion it may cause a seemingly low
hemoglobin concentration due to dilution. However, low
mean arterial blood pressure was not associated with
INSURE failure. Thus, no obvious explanation was found
for this observation. Only two neonates in the INSURE
success group had low hemoglobin, and 32% had missing
values for hemoglobin: thus, the association could be due
to chance. However, in univariate analysis, Cherif et al.
also found that a low hemoglobin concentration increased
the risk of INSURE failure [5]. This potentially strong
association deserves further investigation.
Preeclampsia seemed to reduce the risk for a long dur-
ation of MV. This was rather unexpected because pre-
eclampsia has previously been associated with an increased
risk of BPD in neonates at 23 to 32 weeks gestation
[19]. We consider that neonates born of mothers with-
out preeclampsia may likely be born preterm for some
Table 1 Characteristics of 322 surfactant treated
neonates born before 32 weeks gestation, 1998–2010
Characteristics Study population
(n = 322)
Treatment group, n (%)1
INSURE success 100 (31)
INSURE failure 33 (10)
Short MV 31 (10)
Long MV 158 (49)
Duration of intubation at surfactant,
median (IQR), h1
INSURE success 0.3 (0–0.5)
INSURE failure 0.5 (0–0.7)
Short MV 15.4 (8.0–19.7)
Long MV 57.3 (33.5–114.2)
Gestational age, n (%)1
<26 + 0 weeks 70 (22)
26 + 0 – 27 + 6 weeks 92 (29)
28 + 0 – 29 + 6 weeks 102 (32)
30 + 0 – 31 + 6 weeks 58 (18)
Birth weight, n (%)1
<750 g 53 (17)
750–999 g 104 (32)
1000–1249 g 80 (25)
≥1250 g 84 (26)
Small for gestational age, n (%)1 134 (42)
Gender, n (%), male1 190 (59)









Antenatal steroids, n (%)1 285 (90)
Cesarean delivery, n (%)1 214 (66)
Preeclampsia, n (%)2 59 (20)
Prolonged rupture of membranes >18 hours, n (%)2 26 (9)
Maternal age at delivery, mean (SD), years1 29.9 (4.7)
Abbreviations: h, hours; IQR, interquartile range; long MV, mechanical
ventilation for more than 24 hours; NICU, neonatal intensive care unit; short
MV, mechanical ventilation for less than 24 hours.
Percentage of missing values for each characteristic: 1≤ 5%, and 2≤ 10%.
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turn explain the potentially spurious protective associ-
ation between preeclampsia (relatively benign for theneonate) and long MV. The technical term for this
phenomenon is collider bias, which may arise from con-
ditioning on gestational age [20].
The attending neonatologist may choose not to use
INSURE and keep the most premature or ill neonates on
MV; neonates that would most likely fail the respiratory
challenge of INSURE. Neonates on MV are routinely
evaluated for MV weaning at least every 24 hours. We
assumed that all mechanically ventilated neonates that
would have been INSURE successes if INSURE had been
attempted were extubated within 24 hours. Thus, the
remaining neonates (MV for more than 24 hours) would
all have been INSURE failures, had INSURE been
attempted. The predictors for long MV might be inter-
preted as predictors of INSURE failure. In accordance
with this, the predictors for long MV in the present
study were comparable with the predictors for INSURE
failure found by the two previous studies [5,6]. Further-
more, the post-surfactant characteristics of the popula-
tion (Table 3) were similar in the INSURE success group
and the short MV group, whereas in INSURE failure
group and the long MV group, they were similar. This
supports the above assumption, and we thus might con-
sider predictors for long MV as predictors for INSURE
failure. Consequently, almost all neonates born at our
tertiary center and treated with surfactant were included
in the analyses. This reduces selection bias, increases
power, and increases the external validity.
The neonatologist’s decision on whether or not to treat
the patient with INSURE is the greatest limitation in the
current study. During the first 24 hours after surfactant
administration, neonates on MV were evaluated for MV
weaning. There might be a risk that the neonate was
kept on MV after this evaluation, not because the neo-
nate needed MV, but simply because INSURE failure
was suspected at the initial surfactant administration.
Consequently, the neonate could be kept on MV for
more than 24 hours, even though the neonate would
have been an INSURE success if INSURE had been per-
formed. This could lead to spurious associations with
long MV. However, the predictors for long MV were
similar to predictors for INSURE failure in the former
studies [5,6]. The predictors for long MV might overesti-
mate the true effect because these neonates are usually
in poorer condition than those in the INSURE failure
group, which is indicated by the more severe predictors
(Table 2) and post-surfactant characteristics (Table 3).
The attending neonatologist’s decision to treat a neonate
according to INSURE or MV after surfactant tends to
cause an underestimation of the effect of the predictors
for INSURE failure if the neonatologist suspects the
same set of predictors as those we have evaluated. We
defined INSURE as intubation for less than 2 hours
without the need for MV. This cut-off point was used to
Table 2 Predictors for an unsuccessful INSURE procedure in 291 neonates born before 32 weeks gestation, 1998–2010
Primary analyses
INSURE failure vs. INSURE success
Secondary analyses
Long MV vs. INSURE success
Predictors INSURE success,
n (%) (n = 100)
INSURE failure,
n (%) (n = 33)
Crude OR Adjusted OR
(95% CI)1
Long MV,
n (%) (n = 158)
Crude OR Adjusted OR
(95% CI)1
Gestational age2
30 + 0 – 31 + 6 weeks (base) 34 (34) 3 (9) 1.0 1.0 11 (7) 1.0 1.0
28 + 0 – 29 + 6 weeks 40 (40) 16 (49) 4.5 4.8 (1.3–18.0)* 34 (22) 2.6 3.1 (1.3–7.5)*
26 + 0 – 27 + 6 weeks 18 (18) 8 (24) 5.0 4.9 (1.1–21.2)* 59 (37) 10.1 11.4 (4.6–28.6)*
– 25 + 6 weeks 8 (8) 6 (18) 8.5 9.9 (1.8–55.6)* 54 (34) 20.9 26.3 (9.5–72.5)*
Birth weight <1000 g2 27 (27) 10 (30) 1.2 0.3 (0.1–1.2) 105 (67) 5.5 1.6 (0.8–3.3)
Small for gestational age2 42 (42) 12 (36) 0.8 0.9 (0.4–2.0) 64 (41) 1.0 1.3 (0.7–2.3)
Gender (male)2 57 (57) 19 (58) 1.0 1.4 (0.6–3.2) 97 (61) 1.2 1.4 (0.7–2.6)
Umbilical cord pH <7.35 26 (35) 6 (24) 0.6 0.7 (0.2–2.1) 42 (36) 1.0 1.1 (0.5–2.4)
Umbilical cord
SBE < −3 mmol/l6
18 (26) 5 (24) 0.9 0.6 (0.2–2.0) 46 (42) 2.0 1.3 (0.6–2.8)
Apgar at 1 minute <72 30 (30) 8 (25) 0.8 0.5 (0.2–1.3) 76 (48) 2.2 1.7 (0.9–3.3)
Apgar at 5 minutes <72 4 (4) 2 (6) 1.6 1.4 (0.2–10.6) 23 (15) 4.1 4.7 (1.0–20.9)*
Temp at admission to
NICU <35.5°C3
13 (14) 4 (14) 1.0 0.7 (0.2–2.7) 36 (25) 2.0 1.1 (0.5–2.7)
Surfactant given <5 hours
after birth2
24 (24) 13 (39) 2.1 1.3 (0.5–3.5) 104 (66) 6.1 3.3 (1.7–6.2)*
a/A-ratio <0.204 33 (34) 5 (17) 0.4 0.6 (0.2–1.8) 38 (31) 0.9 1.3 (0.6–2.7)
FiO2 > 0.50
3 31 (33) 9 (29) 0.8 1.3 (0.5–3.6) 74 (50) 2.0 2.7 (1.3–5.3)*
pO2 < 7.5 kPa (~56 mmHg)
5 17 (20) 5 (17) 0.8 0.8 (0.2–2.9) 28 (26) 1.4 1.1 (0.5–2.6)
pCO2 > 7 kPa (~53 mmHg)
4 16 (18) 10 (33) 2.2 2.0 (0.7–5.8) 62 (50) 4.4 4.3 (1.9–9.6)*
pH <7.36 30 (43) 13 (54) 1.5 1.8 (0.7–4.9) 65 (67) 2.6 3.9 (1.7–8.8)*
SBE < −3 mmol/l6 20 (29) 6 (25) 0.8 0.6 (0.2–1.9) 48 (49) 2.4 1.7 (0.7–3.8)
Hemoglobin <8.5 mmol/l6 2 (3) 5 (21) 8.6 5.1 (1.0–25.8)* 14 (15) 5.8 4.8 (0.7–34.7)
Lactate >2.5 mmol/l6 25 (37) 6 (25) 0.6 0.6 (0.2–1.9) 54 (59) 2.4 2.7 (1.3–5.7)*
Mean blood pressure
< gestational age6
9 (13) 2 (12) 0.9 1.0 (0.2–6.9) 16 (17) 1.4 1.7 (0.6–5.2)
Inotropes prior to intubation2 2 (2) 1 (3) 1.5 0.9 (0.2–5.2) 17 (11) 5.9 8.8 (1.2–66.7)*
Nulliparity2 59 (60) 23 (72) 1.7 1.8 (0.7–4.8) 87 (58) 0.9 0.9 (0.5–1.6)
Multiple pregnancy2 45 (45) 16 (48) 1.2 0.9 (0.4–2.1) 66 (42) 0.9 0.6 (0.3–1.1)
Preeclampsia3 24 (26) 8 (25) 0.9 1.2 (0.4–3.2) 18 (12) 0.4 0.4 (0.2–0.8)*
Prolonged rupture of membranes3 8 (8) 1 (3) 0.4 0.2 (0.0–2.2) 16 (11) 1.4 1.1 (0.4–3.4)
Maternal age at delivery >30 years2 48 (48) 16 (48) 1.0 1.3 (0.5–3.0) 86 (55) 1.3 1.6 (0.9–3.1)
No antenatal steroids2 9 (9) 4 (13) 1.4 1.4 (0.4–5.4) 14 (9) 1.0 0.8 (0.3–2.0)
Cesarean delivery (vs. vaginal)2 72 (72) 23 (70) 0.9 1.5 (0.6–4.0) 95 (60) 0.6 1.0 (0.5–1.9)
Abbreviations: a/A-ratio, arterial to alveolar oxygen tension ratio; FiO2, fraction of inspired oxygen; long MV, mechanical ventilation for more than 24 hours; pCO2,
partial pressure of carbon dioxide; pO2, partial pressure of oxygen; SBE, standard base excess; temp, temperature.
*P < 0.05.
1Adjusted for gestational age, gender, and birth year using robust standard error correction for clustering. Gestational age was adjusted for gender and birth year.
Gender was adjusted for gestational age and birth year.
Percentage of missing values for each predictor: 2≤ 5%, 3≤ 10%, 4≤ 20%, 5≤ 30%, and 6≤ 40%.
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ical records by the neonatologists. This may introduce
non-differential information bias, causing bias toward the
null. Finally, a high proportion of values were missing with
regard to some predictors (Table 2).In Cherif et al., the pre-intubation medication was mor-
phine [5]. Information on medication was unavailable in
the study by Dani et al. [6]. Morphine is a long-acting drug
that may increase the risk of INSURE failure and the need
for MV, even though the effect is antagonized with
Table 3 Post-surfactant characteristics for 322 neonates born prior to 32 weeks gestation, 1998–2010









CRIB-score, median (IQR)3 2 (1–2) 2 (2–6)* 2 (2–5)* 6 (2–8)*
CRIB-score > 4, n (%)3 6 (8) 9 (32)* 9 (36)* 79 (66)*
Given < 6 hours after surfactant:
Inotropes, n (%)2 2 (2) 5 (15)* 1 (3) 56 (35)*
Packed red blood cells, n (%)2 6 (6) 3 (9) 1 (3) 18 (11)
Volume expansion, n (%)2 10 (10) 5 (15) 5 (16) 72 (46)*
Antibiotics≥ 7 days, n (%)2 17 (17) 6 (18) 12 (39)* 61 (39)*
Pneumothorax2 2 (2) 8 (25)* 1 (3) 35 (23)*
Necrotizing enterocolitis, n (%)2 10 (10) 8 (24)* 4 (13) 56 (36)*
Clinical suspicion or x-ray changes 9 5 4 50
Surgery 1 3 0 6
Patent ductus arteriosus on first echocardiography, n (%)2 33 (33) 16 (48) 13 (42) 71 (45)
No treatment 19 11 11 49
NSAID/surgery 14 5 2 22
Intraventricular hemorrhage, n (%)2 38 (38) 12 (36) 7 (23) 73 (46)
Grades I–II 34 7 3 32
Grades III–IV 4 5 4 41
Periventricular leukomalasia, n (%)2 4 (4) 1 (3) 2 (6) 15 (9)
BPD, n (%)1,4 12 (18) 5 (26) 4 (24) 27 (46)*
Retinopathy of prematurity grade III, n (%)2 3 (3) 1 (3) 0 (0) 12 (8)
MV days, median (IQR)2 0.01 (0.00–0.03) 3.26 (1.59–4.45)* 0.70 (0.33–0.92)* 3.26 (1.77–6.98)*
CPAP days, median (IQR)2 17.5 (9.3–31.5) 21.5 (10.3–33.1) 19.0 (6.7–34.1) 22.4 (1.2–36.2)
Oxygen days, median (IQR)2 6 (2–20) 10 (4–29) 5 (0–21) 15 (3–40)*
Neonatal death < 28 days, n (%)2 1 (1) 4 (12)* 2 (6) 41 (26)*
Abbreviations: BPD, bronchopulmonary dysplasia; CRIB, clinical risk index for babies; IQR, interquartile range; long MV, mechanical ventilation for more than
24 hours; short MV, mechanical ventilation for less than 24 hours.
*P < 0.05 for the association with INSURE success.
160 neonates died before 36 completed weeks and were thus not included in the analysis.
Percentage of missing values for each post-surfactant characteristic: 2 ≤ 5%, 323%, and 440%.
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http://www.biomedcentral.com/1471-2431/14/155naloxone [21]. The medications used in our population
included both thiomebumal and morphine, which may
account for some of the need for continued MV after
surfactant. However, this is only speculative because
thiomebumal has never been evaluated with respect to
the effect on INSURE failure or need for continued MV
after surfactant [21]. We emphasize that the same pre-
intubation medications were given to all neonates, and
therefore, this could not have confounded the results.
Thus, the pre-intubation medication does not violate
the internal validity of the assessed predictors.
The observational design of this study implies that
causal inference cannot be made. However, if the distribu-
tion of confounders is the same in other settings, the iden-
tified predictors will also predict unsuccessful INSURE in
future populations, even though the associations are not
causal. Whether the identified high-risk neonates wouldhave benefit of being treated with MV immediately after
surfactant instead of INSURE has to be tested in a future
randomized controlled trial. The identified predictors
for an unsuccessful INSURE procedure may be used to
guide a risk stratification for such a future randomized
controlled trial.
Conclusions
We observed an increased risk of INSURE failure in very
preterm neonates with decreasing gestational age at birth
and a low hemoglobin concentration prior to surfactant
administration. Predictors for long duration of MV might
also predict INSURE failure. These predictors were low
gestational age, low Apgar at 5 minutes, high FiO2, high
pCO2, high lactate, low pH, inotropes given prior to intub-
ation, and surfactant administered within 5 hours after
birth. Preeclampsia reduced the risk of long MV. Our
Brix et al. BMC Pediatrics 2014, 14:155 Page 8 of 8
http://www.biomedcentral.com/1471-2431/14/155results can be used to identify neonates at high risk of an
unsuccessful INSURE procedure, which may guide risk
stratification in the clinical setting and planning of a future
randomized controlled trial to assess whether these
high-risk neonates would benefit from treatment with
MV immediately after surfactant instead of INSURE.
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